This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Critchley, I. A.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Critchley, I. A.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 550-555, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.550-555.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Activities of Faropenem, an Oral ß-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

Ian A. Critchley,1 James A. Karlowsky,1* Deborah C. Draghi,1 Mark E. Jones,2 Clyde Thornsberry,1 Kate Murfitt,1 and Daniel F. Sahm1

Focus Technologies, Inc. (formerly MRL), Herndon, Virginia 20171,1 1217 KP Hilversum, The Netherlands2

Received 25 July 2001/ Returned for modification 11 September 2001/ Accepted 15 October 2001

The in vitro activities of faropenem and other antimicrobial agents were determined against 4,725 Streptococcus pneumoniae isolates, 2,614 Haemophilus influenzae isolates, and 1,193 Moraxella catarrhalis isolates collected from 273 U.S. laboratories during 1999. Faropenem MICs at which 90% of isolates are inhibited were 0.008, 0.25, and 1 µg/ml for penicillin-susceptible, -intermediate, and -resistant S. pneumoniae strains, respectively; 0.5 and 1 µg/ml for ß-lactamase-positive and -negative H. influenzae strains, respectively; and 0.12 and 0.5 µg/ml for ß-lactamase-negative and -positive M. catarrhalis strains, respectively. Faropenem holds promise as an oral therapy for community-acquired respiratory tract infections.

* Corresponding author. Mailing address: Focus Technologies, Inc., 13665 Dulles Technology Dr., Suite 200, Herndon, VA 20171-4603. Phone: (703) 480-2500. Fax: (703) 480-2670. E-mail: jkarlowsky{at}focusanswers.com.

Antimicrobial Agents and Chemotherapy, February 2002, p. 550-555, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.550-555.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gettig, J. P, Crank, C. W, Philbrick, A. H (2008). Faropenem Medoxomil. The Annals of Pharmacotherapy 42: 80-90 [Abstract] [Full Text]  
  • Critchley, I. A., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2007). National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study. Antimicrob. Agents Chemother. 51: 4382-4389 [Abstract] [Full Text]  
  • Stone, K. C., Dagan, R., Arguedas, A., Leibovitz, E., Wang, E., Echols, R. M., Janjic, N., Critchley, I. A. (2007). Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel. Antimicrob. Agents Chemother. 51: 2230-2235 [Abstract] [Full Text]  
  • Kosowska, K., Jacobs, M. R., Bajaksouzian, S., Koeth, L., Appelbaum, P. C. (2004). Alterations of Penicillin-Binding Proteins 1A, 2X, and 2B in Streptococcus pneumoniae Isolates for Which Amoxicillin MICs Are Higher than Penicillin MICs. Antimicrob. Agents Chemother. 48: 4020-4022 [Abstract] [Full Text]  
  • Credito, K. L., Jacobs, M. R., Appelbaum, P. C. (2003). In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill. J Antimicrob Chemother 51: 1437-1439 [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2002). Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother 50: 411-420 [Abstract] [Full Text]  
  • Jones, M. E., Karlowsky, J. A., Blosser-Middleton, R., Critchley, I. A., Karginova, E., Thornsberry, C., Sahm, D. F. (2002). Longitudinal Assessment of Antipneumococcal Susceptibility in the United States. Antimicrob. Agents Chemother. 46: 2651-2655 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»